HER2 Support Group Forums - View Single Post - current sept 06 MAMM issue artile on herceptin + PI3K Inhibitor...

heblaj01 · 09-28-2006, 06:26 PM

One of the other PI3K inhibitors that Dr Dihua Yu is alluding to may be the experimental drug SF1126 being considered also at MD Anderson for clinical trial:

http://www.semaforepharma.com/pdf/AARC_040406_FINAL.pdf

NEW DATA PRESENTED AT AACR MEETING FURTHER SUPPORT THE ADVANCE OF SEMAFORE’S TARGETED PI3K INHIBITOR INTO PHASE l TRIALS

--Studies at M.D. Anderson Show First In Vivo FDG-PET Imaging of SF1126 and Demonstrate Mutational Activation of PI3K as a Potential Marker for Selection of Patients—

However in a detailed discussion in the following article of the mode of action of some of the PI3K inhibitors some of their potential serious side effects are considered :

http://www.pubmedcentral.gov/articlerender.fcgi?artid=1236693

The survival kinases Akt and Pim as potential pharmacological targets

09-28-2006, 06:26 PM	#2
heblaj01 Senior Member Join Date: Apr 2006 Posts: 543	One of the other PI3K inhibitors that Dr Dihua Yu is alluding to may be the experimental drug *SF1126* being considered also at MD Anderson for clinical trial: http://www.semaforepharma.com/pdf/AARC_040406_FINAL.pdf NEW DATA PRESENTED AT AACR MEETING FURTHER SUPPORT THE ADVANCE OF SEMAFORE’S TARGETED PI3K INHIBITOR INTO PHASE l TRIALS --Studies at M.D. Anderson Show First In Vivo FDG-PET Imaging of SF1126 and Demonstrate Mutational Activation of PI3K as a Potential Marker for Selection of Patients— However in a detailed discussion in the following article of the mode of action of some of the PI3K inhibitors some of their potential serious side effects are considered : http://www.pubmedcentral.gov/articlerender.fcgi?artid=1236693 The survival kinases Akt and Pim as potential pharmacological targets